OMKAR PHARMACHEM LTD. is a Chemicals & Petrochemicals company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 0 |
| EBITDA (ex other income) | 0 | 0 | 0 | 0 | 0 |
| margin % | 49.7 | 57.5 | 52.5 | 53.7 | 34.6 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 0.18 | 0.20 | 0.19 | 0.20 | 26.98 |
| ROE % · ROCE % | 2.1 · 3.0 | 2.2 · 3.4 | 2.0 · 3.1 | 2.1 · 3.0 | 0.3 · 0.5 |
| Debt / equity (x) | 0.11 | 0.07 | 0.03 | 0.01 | 0.00 |
| Cash from operations | 0 | 0 | 0 | 0 | 0 |
| Capex | (0) | 0 | (0) | (0) | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.05 | 0.09 | 0.08 | 0.02 | 0.02 | 0.05 | 0.03 | 26.87 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DEEPAK FERTILIZERS & PETR | 16,727 | 17.0 | 2.24 | 12.2 | 9.9 | 8.4 | 14.6 | 26.1 |
| TATA CHEMICALS LTD | 15,683 | — | 0.71 | 141.2 | (7.7) | (5.0) | 7.4 | 14.4 |
| GUJ NAR VAL FER & CHEM L | 8,273 | 8.0 | 0.91 | 6.0 | 8.9 | 10.3 | 8.7 | 22.1 |
| TANFAC INDUSTRIES LTD. | 6,773 | 55.4 | 18.15 | — | 18.8 | 24.3 | — | 16.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Omkar Pharmachem 31st AGM notice filed with BSE | compliance | minimal | — | — |
| 2 Sept 2026 · Cut-off date set for e-voting at 31st AGM on 23 Sept 2026 | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Omkar Pharmachem 31st Annual Report FY26 and AGM Notice filed | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Omkar Pharmachem 31st AGM notice - Sept 30, 2026, three items on agenda | board shareholder meetings | low | — | — |
| 31 Aug 2026 · Board approves 31st AGM notice on September 30, 2026 | board shareholder meetings | low | — | — |
| 14 Aug 2026 · Omkar Pharmachem Q1 FY27 Results Published - Swings to Loss | compliance | minimal | — | — |
| 13 Aug 2026 · Q1 FY27 loss as zero revenue continues; PAT slips to Rs. 1 lakh loss | results | high | — | — |
| 13 Aug 2026 · Omkar Pharmachem Q1 FY27 results: loss of Rs 1 lakh vs profit last year | results | high | — | — |
| 6 Aug 2026 · Board meeting on Aug 13 to consider Q1 FY27 results | results | low | — | — |
| 18 Jul 2026 · Newspaper ad on special window to demat physical shares | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| GUJARAT ALKALIES & CHEM |
| 5,179 |
| 78.0 |
| 1.00 |
| 10.7 |
| (0.0) |
| 0.7 |
| 12.4 |
| 18.4 |
| GHCL LIMITED | 3,879 | 8.4 | 1.09 | 5.1 | 13.3 | 16.6 | 1.1 | 23.9 |
| GRAUER & WEIL IND LTD | 3,469 | 21.2 | 3.21 | 14.1 | 15.2 | 19.2 | 14.5 | 20.4 |
| J.G.CHEMICALS LIMITED | 2,330 | 31.0 | 4.31 | 23.7 | 12.7 | 16.9 | — | 11.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 0.3 | 17.0 | 2 of 57 | 98% |
| P/B | 0.2 | 1.4 | 2 of 59 | 98% |
| ROCE | 0.4 | 6.2 | 51 of 65 | 22% |
| ROE | 0.3 | 4.9 | 50 of 65 | 23% |
| Debt / Equity | 0.0 | 0.2 | 7 of 65 | 78% |
| EBITDA margin | 22.6 | 13.3 | 9 of 58 | 86% |
| Revenue growth | (33.3) | 6.7 | 48 of 54 | 11% |
| Profit growth | 169.8 | 21.0 | 13 of 64 | 81% |
| Market cap | 8 | 77 | 63 of 65 | 3% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
